StockDuty ← Dashboard Aug 11, 2026 08:56 AM ET
CatalystFDA/Bio

Oruka Q2 Net Loss Expands; Expects Phase 2 EVERLAST-A 28 Week Data Of ORKA-001 At The End Of Q3 2026

Oruka Q2 Net Loss Expands; Expects Phase 2 EVERLAST-A 28 Week Data Of ORKA-001 At The End Of Q3 2026

What changed
Oruka Q2 Net Loss Expands; Expects Phase 2 EVERLAST-A 28 Week Data Of ORKA-001 At The End Of Q3 2026
Why it matters
Oruka Q2 Net Loss Expands; Expects Phase 2 EVERLAST-A 28 Week Data Of ORKA-001 At The End Of Q3 2026 — impact context not separately stored; see What changed.
Sources
eodhd
Related signals
PHASE 1 OF INDIA - US TRADE PACT HINGES ON SECTION 301 PROBE , OFFICIAL SAYS →PITNEY BOWES OUTLINES PHASE 2 STRATEGIC REVIEW WHILE PUSHING NEAREST DEBT MATURITY TO MARCH 2029 - SEEKINGALPHA →UNICYCIVE PLUMMETS FOLLOWING SECOND CRL FOR OLC FOR HYPERPHOSPHATEMIA - SEEKINGALPHA →